Influence of CYP2B6 activity score on the pharmacokinetics and safety of single dose efavirenz in healthy volunteers

被引：11

作者：

Zubiaur, Pablo ^{[1
]}

Saiz-Rodriguez, Miriam ^{[1
]}

Ochoa, Dolores ^{[1
,2
]}

Belmonte, Carmen ^{[1
,2
]}

Roman, Manuel ^{[1
,2
]}

Mejia, Gina ^{[1
,2
]}

Martin-Vilchez, Samuel ^{[1
]}

Abad-Santos, Francisco ^{[1
,2
,3
,4
]}

机构：

[1] UAM, Hosp Univ La Princesa, Inst Invest Sanitaria La Princesa IP, Clin Pharmacol Dept,Inst Teofilo Hernando, Madrid, Spain

[2] UICEC Hosp Univ La Princesa, Plataforma SCReN Spanish Clin Res Network, Inst Invest Sanitaria La Princesa IP, Madrid, Spain

[3] Inst Salud Carlos III, CIBERehd, Madrid, Spain

[4] Univ Autonoma Madrid, Fac Med, Pharmacol Dept, Madrid, Spain

来源：

PHARMACOGENOMICS JOURNAL | 2020年 / 20卷 / 02期

关键词：

TRANSCRIPTASE INHIBITOR EFAVIRENZ; 600; MG; PLASMA; PHARMACOGENETICS; IDENTIFICATION; IMPACT; GENE; POLYMORPHISMS; INDIVIDUALS; METABOLISM;

D O I：

10.1038/s41397-019-0103-3

中图分类号：

Q3 [遗传学];

学科分类号：

071007 ; 090102 ;

摘要：

Efavirenz is a non-nucleoside reverse transcriptase inhibitor used as first-line therapy for the treatment of HIV infection. Cytochrome P450 (CYP) CYP2B6 G516T (rs3745274) is a well-known predictor of efavirenz disposition. Dose adjustment based on G516T variant has been shown to be beneficial. However, this variant cannot explain the entire variability of efavirenz pharmacokinetics. In this study, we evaluated the influence of 11 single-nucleotide polymorphisms (SNPs) in CYP2B6, CYP2A6, CYP3A and ABCB1 (ATP-binding cassette sub-family B member 1) on the pharmacokinetics and safety of efavirenz after single oral dose administration to 47 healthy volunteers. We designed and validated a CYP2B6 activity score model based on two CYP2B6 SNPs (G516T and rs4803419) that predicted efavirenz disposition better than G516T alone.

引用

页码：235 / 245

页数：11

共 40 条

[1] Tell-Tale SNPs: The Role of CYP2B6 in Methadone Fatalities [J].

Ahmad, Taha ;

Sabet, Samie ;

Primerano, Donald A. ;

Richards-Waugh, Lauren L. ;

Rankin, Gary O. .

JOURNAL OF ANALYTICAL TOXICOLOGY, 2017, 41 (04) :325-333

[2] A global reference for human genetic variation [J].

Altshuler, David M. ;

Durbin, Richard M. ;

Abecasis, Goncalo R. ;

Bentley, David R. ;

Chakravarti, Aravinda ;

Clark, Andrew G. ;

Donnelly, Peter ;

Eichler, Evan E. ;

Flicek, Paul ;

Gabriel, Stacey B. ;

Gibbs, Richard A. ;

Green, Eric D. ;

Hurles, Matthew E. ;

Knoppers, Bartha M. ;

Korbel, Jan O. ;

Lander, Eric S. ;

Lee, Charles ;

Lehrach, Hans ;

Mardis, Elaine R. ;

Marth, Gabor T. ;

McVean, Gil A. ;

Nickerson, Deborah A. ;

Wang, Jun ;

Wilson, Richard K. ;

Boerwinkle, Eric ;

Doddapaneni, Harsha ;

Han, Yi ;

Korchina, Viktoriya ;

Kovar, Christie ;

Lee, Sandra ;

Muzny, Donna ;

Reid, Jeffrey G. ;

Zhu, Yiming ;

Chang, Yuqi ;

Feng, Qiang ;

Fang, Xiaodong ;

Guo, Xiaosen ;

Jian, Min ;

Jiang, Hui ;

Jin, Xin ;

Lan, Tianming ;

Li, Guoqing ;

Li, Jingxiang ;

Li, Yingrui ;

Liu, Shengmao ;

Liu, Xiao ;

Lu, Yao ;

Ma, Xuedi ;

Tang, Meifang ;

Wang, Bo .

NATURE, 2015, 526 (7571) :68-+

[3] Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study [J].

Amin, Janaki ;

Becker, Stephen ;

Belloso, Waldo ;

To, Marta Boffi ;

Cooper, David ;

Crabtree-Ramirez, Brenda ;

Duncombe, Chris ;

Emery, Sean ;

Foulkes, Sharne ;

Hill, Andrew ;

Jessen, Heiko ;

Kumar, Suresh ;

Lee, Man-Po ;

Losso, Marcelo ;

Nwizu, Chidi ;

Phanuphak, Praphan ;

Rooney, Tim Read Jim ;

Er, Kim Schaff ;

Shahar, Eduardo ;

Winston, Alan ;

Wolff, Marcelo ;

Young, Barnaby ;

Abela, Cecilia ;

Amin, Janaki ;

Avihingsanon, Anchalee ;

Belloso, Waldo ;

Boyd, Mark ;

Carey, Dianne ;

Clarke, Amanda ;

Cooper, David ;

Courtney-Vega, Kymme ;

No, Marina Delfi ;

Donaldson, Anna ;

Emery, Sean ;

Espinosa, Natalie ;

Johannesen, Tanya ;

Lin, Enmoore ;

Losso, Marcelo ;

Moricz, Alejandra ;

Pett, Sarah ;

Phanupak, Praphan ;

Puls, Rebekah ;

Pussadee, Kanitta ;

Sutheerasak, Parinya ;

Tomlins, Louise ;

Ubolyam, Sasiwimol ;

Belloso, Waldo ;

Azwa, Raja Iskandar Shah bin Raja ;

Bissio, Emiliano ;

Calanni, Liliana .

LANCET INFECTIOUS DISEASES, 2015, 15 (07) :793-802

[4] High frequency and founder effect of the CYP3A4*20 loss-of-function allele in the Spanish population classifies CYP3A4 as a polymorphic enzyme [J].

Apellaniz-Ruiz, M. ;

Inglada-Perez, L. ;

Naranjo, M. E. G. ;

Sanchez, L. ;

Mancikova, V. ;

Curras-Freixes, M. ;

de Cubas, A. A. ;

Comino-Mendez, I. ;

Triki, S. ;

Rebai, A. ;

Rasool, M. ;

Moya, G. ;

Grazina, M. ;

Opocher, G. ;

Cascon, A. ;

Taboada-Echalar, P. ;

Ingelman-Sundberg, M. ;

Carracedo, A. ;

Robledo, M. ;

Llerena, A. ;

Rodriguez-Antona, C. .

PHARMACOGENOMICS JOURNAL, 2015, 15 (03) :288-292

[5] Efavirenz: What is known about the cellular mechanisms responsible for its adverse effects [J].

Apostolova, Nadezda ;

Blas-Garcia, Ana ;

Galindo, Maria J. ;

Esplugues, Juan V. .

EUROPEAN JOURNAL OF PHARMACOLOGY, 2017, 812 :163-173

[6] The impact of genetic polymorphisms on the pharmacokinetics of efavirenz in African children [J].

Bienczak, Andrzej ;

Cook, Adrian ;

Wiesner, Lubbe ;

Olagunju, Adeniyi ;

Mulenga, Veronica ;

Kityo, Cissy ;

Kekitiinwa, Addy ;

Owen, Andrew ;

Walker, A. Sarah ;

Gibb, DianaM. ;

McIlleron, Helen ;

Burger, David ;

Denti, Paolo .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 82 (01) :185-198

[7] Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz:: the effect of gender, race, and CYP2B6 polymorphism [J].

Burger, D ;

van der Heiden, I ;

la Porte, C ;

van der Ende, M ;

Groeneveld, P ;

Richter, C ;

Koopmans, P ;

Kroon, F ;

Sprenger, H ;

Lindemans, J ;

Schenk, P ;

van Schaik, R .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 61 (02) :148-154

[8] Durability of Efavirenz Compared With Boosted Protease Inhibitor-Based Regimens in Antiretroviral-Naive Patients in the Caribbean and Central and South America [J].

Caro-Vega, Yanink ;

Belaunzaran-Zamudio, Pablo F. ;

Crabtree-Ramirez, Brenda E. ;

Shepherd, Bryan E. ;

Grinsztejn, Beatriz ;

Wolff, Marcelo ;

Pape, Jean W. ;

Padgett, Denis ;

Gotuzzo, Eduardo ;

McGowan, Catherine C. ;

Sierra-Madero, Juan G. .

OPEN FORUM INFECTIOUS DISEASES, 2018, 5 (03)

[9] Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection [J].

Csajka, C ;

Marzolini, C ;

Fattinger, K ;

Décosterd, LA ;

Fellay, J ;

Telenti, A ;

Biollaz, J ;

Buclin, T .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 73 (01) :20-30

[10] Efavirenz pharmacogenetics in a cohort of Italian patients [J].

Cusato, Jessica ;

Tomasello, Cristina ;

Simiele, Marco ;

Calcagno, Andrea ;

Bonora, Stefano ;

Marinaro, Letizia ;

Leggieri, Anna ;

Allegra, Sarah ;

Di Perri, Giovanni ;

D'Avolio, Antonio .

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2016, 47 (02) :117-123

← 1 2 3 4 →